Syndax Pharmaceuticals
Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company that develops and markets first-in-class targeted therapies for acute leukemias and chronic graft-versus-host disease, anchored by Revuforj (menin inhibitor) and Niktimvo (anti-CSF-1R antibody), serving U.S. and international oncology and transplant patients through direct sales and partnerships.
- Company typePublic
- Founded2005
- HeadquartersWaltham, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Syndax Pharmaceuticals does
Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company founded in October 2005 by Peter Ordentlich, Ph.D., that develops first-in-class targeted therapies for acute leukemias and chronic graft-versus-host disease (GVHD). The company is publicly traded on Nasdaq under ticker SNDX and operates from New York City (headquartered at 730 3rd Avenue), with additional operations referenced in Waltham, Massachusetts. Its portfolio is anchored by two FDA-approved products: Revuforj (revumenib), a first-in-class selective menin inhibitor approved for relapsed or refractory KMT2A-rearranged acute leukemia in 2024 and for NPM1-mutated acute myeloid leukemia (AML) in October 2025; and Niktimvo (axatilimab-csfr), a first-in-class anti-CSF-1R monoclonal antibody approved for chronic GVHD in August 2024 and co-promoted with Incyte in the United States. The company also retains an entinostat program (a Class I HDAC inhibitor) that has been deprioritized and licensed to Eddingpharm for China and certain Asian countries, where it has received marketing approval.
The company's technology rests on two proprietary platforms: menin inhibition (disrupting the menin-KMT2A protein-protein interaction to halt leukemic cell transcription programs driven by HOX and MEIS genes) and anti-CSF-1R monoclonal antibody technology (blocking colony stimulating factor-1 receptor signaling to reduce disease-mediating monocytes and macrophages in fibrotic conditions). Clinical performance has been category-defining: Revuforj demonstrated 88% overall response rate and 71% composite complete remission rate in the SAVE trial in relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML; 97% composite CR rate in newly diagnosed NPM1m/KMT2Ar AML in combination with intensive chemotherapy; and 90% two-year overall survival as maintenance post-transplant versus a 51% historical comparator. Niktimvo delivered 74% overall response rate in the AGAVE-201 trial in chronic GVHD patients who failed prior therapies. The pipeline extends into earlier-line settings, maintenance therapy, combination regimens (including with venetoclax and azacitidine), and additional indications such as idiopathic pulmonary fibrosis for axatilimab.
Syndax generates revenue through direct U.S. commercialization of Revuforj via an enterprise field sales force targeting oncologists, hematologists, and transplant centers, plus collaboration revenue from the Incyte co-promotion of Niktimvo. International reach is delivered through partner channels: Specialised Therapeutics (Australia, New Zealand, Singapore, with TGA approval secured in 2026), the World Orphan Drug Alliance (managed access program covering Eurasia, Central/Southeast Europe, Middle East, Turkey, Latin America, and Africa), and Eddingpharm (entinostat in Asia). FY2025 revenue totaled $172.4 million (Revuforj net revenue $124.8M, Niktimvo collaboration revenue $42.4M), and Q1 2026 revenue of $64.9 million represented 224% year-over-year growth, with a $394 million cash position at year-end 2025 supporting continued investment in commercial scaling and pipeline expansion.
Syndax Pharmaceuticals firmographics
Firmographics- Name
- Syndax Pharmaceuticals
- Legal name
- Syndax Pharmaceuticals, Inc.
- Website
- https://syndax.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company that develops and markets first-in-class targeted therapies for acute leukemias and chronic graft-versus-host disease, anchored by Revuforj (menin inhibitor) and Niktimvo (anti-CSF-1R antibody), serving U.S. and international oncology and transplant patients through direct sales and partnerships.
- Ownership category
- akta.pro rank
Syndax Pharmaceuticals industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Syndax Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Syndax Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Revuforj (revumenib) Sales: Revuforj is an FDA-approved menin inhibitor for treating relapsed or refractory KMT2Ar acute leukemia and NPM1m AML. The drug generated $124.8 million in full-year 2025 net revenue and $48.9 million in Q1 2026 net revenue. The company markets the drug directly through its commercial organization.
- Niktimvo (axatilimab) Collaboration Revenue: Niktimvo is an FDA-approved anti-CSF-1R antibody for chronic graft-versus-host disease. Syndax co-promotes the drug with strategic partner Incyte. The company received $42.4 million in Niktimvo collaboration revenue for full-year 2025, and Niktimvo generated $151.6 million in revenue to partner Incyte. Niktimvo achieved $55.1 million in Q1 2026.
- Entinostat Licensing (China/Asia): Syndax maintains a license, development and commercialization agreement with Eddingpharm International Company Limited for entinostat in China and certain other Asian countries. The drug received marketing approval in China.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Revuforj is a prescription pharmaceutical product with pricing subject to state reporting requirements |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Syndax Pharmaceuticals product offering
Product offeringCore offering
Syndax Pharmaceuticals develops and commercializes first-in-class targeted oncology therapies, with two FDA-approved drugs on the U.S. market: Revuforj (revumenib), a selective menin inhibitor for relapsed/refractory KMT2A-rearranged acute leukemia and NPM1-mutated AML, and Niktimvo (axatilimab-csfr), an anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease. The company supplements direct product sales with co-promotion revenue (Incyte), ex-U.S. distribution partnerships, and licensing royalties on its deprioritized HDAC inhibitor entinostat in Asia.
Product overview
Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved cancer therapies: Revuforj® (revumenib), a first-in-class menin inhibitor approved for relapsed or refractory KMT2A-rearranged and NPM1-mutated acute leukemias, and Niktimvo™ (axatilimab-csfr), a first-in-class anti-CSF-1R antibody approved for chronic graft-versus-host disease. The company also has pipeline programs including revumenib in earlier-line settings and combination therapies, and axatilimab in idiopathic pulmonary fibrosis and frontline chronic GVHD. Entinostat, a Class I HDAC inhibitor, has been deprioritized with rights licensed to Eddingpharm for Asia. The company's focus areas include acute leukemias (KMT2Ar and NPM1m subtypes) and chronic GVHD.
Differentiator
Problem solved
Functional benefit
Brands
- Revuforj: FDA-approved menin inhibitor for treating relapsed or refractory acute leukemia with KMT2A translocation or NPM1 mutation
- Niktimvo
- SyndAccess
Products and services
- Revuforj (revumenib) First-in-class selective menin inhibitor approved by the FDA for the treatment of adult and pediatric patients with relapsed or refractory KMT2A-rearranged acute leukemia (2024) and relapsed or refractory NPM1-mutated acute myeloid leukemia (October 2025). Revumenib works by disrupting the menin-KMT2A protein-protein interaction, turning off HOX and MEIS gene expression to halt leukemic cell growth. Generated $124.8M in FY2025 net revenue and was the highest first-year revenue AML product at $125M.
- Niktimvo (axatilimab-csfr) First-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking monoclonal antibody approved by the FDA for chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. Axatilimab reduces disease-mediating macrophages and their monocyte precursors to address the fibrotic disease process underlying chronic GVHD. Co-promoted with Incyte in the United States; generated $42.4M collaboration revenue in FY2025 with $151.6M in partner Incyte sales.
- Entinostat (SNDX-275) Selective, oral, once-weekly Class I HDAC inhibitor previously studied in multiple solid tumors in combination with hormone therapy and checkpoint inhibitors. Entinostat is thought to re-sensitize cells to endocrine therapy and demonstrates synergistic anti-tumor activity with immune checkpoint inhibitors. Development has been deprioritized; commercial rights in China and certain other Asian countries are licensed to Eddingpharm International Company Limited under a license, development and commercialization agreement, with marketing approval received in China.
Quantifiable outcome
- 88% overall response rate in relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML patients (SAVE trial)
- +5 more outcomes
Companies that use Syndax Pharmaceuticals
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Syndax Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Syndax Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered regional, core and minor.
- Specialised TherapeuticsregionalExclusive partnership to commercialize NiktimVO (axatilimab) in Australia, New Zealand, and Singapore. Specialised Therapeutics pursued reimbursement through the Pharmaceutical Benefits Scheme in Australia following TGA approval.
- IncytecoreStrategic co-promotion partnership for Niktimvo (axatilimab-csfr) in the United States. Syndax and Incyte collaborate on commercialization with Incyte handling patient support through IncyteCARES program. The partnership leverages both companies' hematology/oncology commercial infrastructure.
- Eddingpharm International Company LimitedminorLicensing agreement granting Eddingpharm exclusive rights to develop and commercialize entinostat in China and certain other Asian countries. Entinostat received marketing approval in China under this agreement.
- World Orphan Drug Alliance (WODA)minorCollaboration for Syndax-WODA Managed Access Program providing revumenib to patients in regions where not yet commercially available. WODA provides the drug through its network of members on a named patient basis in parts of Eurasia, Central/Southeast Europe, Middle East, Turkey, Latin America, and Africa.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Syndax Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Kura Oncology: Clinical-stage oncology company developing menin inhibitors (KO-539) for KMT2A-rearranged and NPM1-mutant acute leukemias — directly competing with Syndax's Revuforj in the same molecular target and indications.
- Incyte: Strategic partner that co-promotes Niktimvo with Syndax in the U.S., but also a competitor in chronic GVHD through ruxolitinib (Jakafi) — providing both commercial leverage and overlap in target indications.
- Sanofi: Markets Rezurock (belumosudil) for chronic graft-versus-host disease after transplant, directly competing with Syndax's Niktimvo in the same indication and third-line-plus patient population.
- Jazz Pharmaceuticals: Specialty biopharma developing ziftomenib, a menin inhibitor for KMT2A-rearranged AML, in direct competition with Syndax's Revuforj across the same genetic subtype and indication.
Broad incumbents
- Daiichi Sankyo: Japanese global biopharma with strong antibody-drug conjugate and hematology/oncology pipeline; comparable as a specialty hematology/oncology innovator with similar first-in-class development focus.
- AbbVie: Major oncology and immunology biopharma with broad hematology and transplant-related franchises; competes in adjacent specialty pharma indications including leukemia and post-transplant complications.
- Pfizer: Large diversified biopharma with significant oncology and hematology presence including active menin inhibition research through partnerships; competes broadly with Syndax in acute leukemia treatment settings.
- Bristol-Myers Squibb: Large oncology incumbent with broad hematology portfolio and active menin inhibitor research (incoming Head of R&D Nick Botwood came from BMS); competes broadly across AML/GVHD treatment paradigms.
Emerging players
- Forma Therapeutics (Novo Nordisk): Developed FTX-6058 and a menin inhibitor program for AML before being acquired by Novo Nordisk; overlaps with Syndax in the menin inhibition mechanism and hematologic oncology target space.
- Foghorn Therapeutics: Clinical-stage biotech developing FHD-286, a menin inhibitor for AML — competing with Syndax's Revuforj in the same molecular target space with a focused but earlier-stage pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Syndax Pharmaceuticals social profiles
Digital presenceSyndax Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Syndax Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles8 records
Syndax Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds16 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Syndax Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Syndax Pharmaceuticals
What does Syndax Pharmaceuticals do?
Syndax Pharmaceuticals develops and commercializes first-in-class targeted oncology therapies, with two FDA-approved drugs on the U.S. market: Revuforj (revumenib), a selective menin inhibitor for relapsed/refractory KMT2A-rearranged acute leukemia and NPM1-mutated AML, and Niktimvo (axatilimab-csfr), an anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease. The company supplements direct product sales with co-promotion revenue (Incyte), ex-U.S. distribution partnerships, and licensing royalties on its deprioritized HDAC inhibitor entinostat in Asia.
Is Syndax Pharmaceuticals a public or private company?
Syndax Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Syndax Pharmaceuticals founded?
Syndax Pharmaceuticals was founded in 2005. It employs 251 to 500 people.
Where is Syndax Pharmaceuticals based?
Syndax Pharmaceuticals is headquartered in Waltham, United States, in the North America region.
How does Syndax Pharmaceuticals make money?
Three revenue lines are on record. Revuforj (revumenib) Sales are the primary driver. The others are niktimvo (axatilimab) Collaboration Revenue and entinostat Licensing (China/Asia).
Who are Syndax Pharmaceuticals's main competitors?
Direct peers on record are Kura Oncology, Incyte, Sanofi and Jazz Pharmaceuticals. Broad incumbents are Daiichi Sankyo, AbbVie, Pfizer and Bristol-Myers Squibb. Emerging players are Forma Therapeutics (Novo Nordisk) and Foghorn Therapeutics.
Does Syndax Pharmaceuticals have an API?
No public API is recorded for Syndax Pharmaceuticals.
What industry is Syndax Pharmaceuticals in?
Syndax Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.